Prevalence of drug-resistant tuberculosis in Zimbabwe: A health facility-based cross-sectional survey

Prevalence of resistance to rifampicin alone; rifampicin and isoniazid, and second-line anti-TB drugs among sputum smear-positive TB patients

Abstract

This study aims to determine the prevalence of resistance to rifampicin alone; rifampicin and isoniazid, and second-line anti-TB drugs among sputum smear-positive tuberculosis patients in Zimbabwe.

This research was supported by the UK Department for International Development’s Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)

Citation

Timire C, Metcalfe JZ, Chirenda J, Scholten JN, Manyame-Murwira B, Ngwenya M, Matambo R, Charambira K, Mutunzi H, Kalisvaart N, Sandy C. Prevalence of drug-resistant tuberculosis in Zimbabwe: A health facility-based cross-sectional survey. International Journal of Infectious Diseases. 2019;87:119–25.

Prevalence of drug-resistant tuberculosis in Zimbabwe: A health facility-based cross-sectional survey

Updates to this page

Published 27 July 2019